In één alinea
Lilly is one of the world's largest pharmaceutical companies. It entered gene editing by buying Verve Therapeutics in 2025 for around a billion dollars, acquiring a programme designed to lower cholesterol permanently with a single treatment. The purchase is a signal that large pharmaceutical companies now see in vivo editing as a serious commercial proposition rather than a science project.
Eli Lilly and Company acquired Verve Therapeutics in 2025 for approximately $1 billion plus contingent value rights, adding in vivo base editing for cardiovascular disease to a portfolio spanning metabolic, oncology and neuroscience medicines. The transaction is among the clearest indications of large-pharma conviction in the modality.
Sources
- Eli Lilly and Company · 2025
Lilly to acquire Verve Therapeutics ↗
Geen beleggingsadvies
Dit profiel is educatieve informatie samengesteld uit openbare bekendmakingen. Het is geen aanbeveling om een effect te kopen, verkopen of aan te houden, en het is geen mening over de vooruitzichten van het bedrijf. Biotechnologie is sterk speculatief en de meeste klinische programma's mislukken.
Volledige disclaimers →